As biosimilars struggle to live up to their promise of cutting costs and improving access to biologic medicines for U.S. patients, more than 39 advocacy groups are championing recent bipartisan efforts to cut through the bureaucracy that they believe has
read moreBiopharma layoff rounds reported this May hit an all-time high, with 29 RIFs occurring—the most of any month reported over the last four years Fierce Biotech has spent tracking the measure. More: Biopharma layoffs for first half of the year
read more
New trial to test VMX-C001’s effectiveness in restoring coagulation in FXa DOAC patients More: VarmX secures US approval to begin phase 3 trial of urgent surgery treatment Source: News
read more
Enter the 2025 PharmaTimes Clinical Researcher of the Year – The Americas More: Clinical Researcher of the Year – The Americas Source: News
read moreThe airline accused more than 40 generic drugmakers of engaging in a wide-spanning price-fixing scheme that allegedly cost the company “hundreds of millions” of dollars over the years. More: Southwest Airlines sues dozens of generic drugmakers for alleged price-fixing scheme
read moreSeveral months after the FDA signed off on Bimzelx’s label expansion into hidradenitis suppurativa, UCB is expanding an existing campaign to include the drug’s new indication. More: UCB extends Bimzelx ad campaign in wake of hidradenitis suppurativa approval Source: fierce
read more© 1994 - 2025 B.M. Pharmaceuticals